Literature DB >> 111704

Treatment of amoeboid herpetic ulcers with adenine arabinoside or trifluorothymidine.

D J Coster, B R Jones, J I McGill.   

Abstract

In previous studies adenine arabinoside and trifluorothymidine were found to be equally effective treatments for dendritic ulcers of the cornea, but a trend emerged which suggested that in amoeboid ulcers trifluorothymidine was more effective. The collection of additional cases confirms the superiority of trifluorothymidine in such cases.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 111704      PMCID: PMC1043501          DOI: 10.1136/bjo.63.6.418

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  5 in total

1.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

2.  Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers.

Authors:  P C Wellings; P N Awdry; F H Bors; B R Jones; D C Brown; H E Kaufman
Journal:  Am J Ophthalmol       Date:  1972-06       Impact factor: 5.258

3.  Clinical evaluation of adenine arabinoside and idoxuridine in the treatment of ocular herpes simplex.

Authors:  D Pavan-Langston
Journal:  Am J Ophthalmol       Date:  1975-09       Impact factor: 5.258

4.  Clinical evaluation of adenine arabinoside and trifluorothymidine in the treatment of corneal ulcers caused by herpes simplex virus.

Authors:  D J Coster; J R McKinnon; J I McGill; B R Jones; F T Fraunfelder
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

5.  Topical therapy of ulcerative herpetic keratitis with human interferon.

Authors:  B R Jones; D J Coster; M G Falcon; K Cantell
Journal:  Lancet       Date:  1976-07-17       Impact factor: 79.321

  5 in total
  12 in total

Review 1.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

2.  Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice.

Authors:  R F Schinazi; J Peters; C C Williams; D Chance; A J Nahmias
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

3.  A comparison of acyclovir and idoxuridine as treatment for ulcerative herpetic keratitis.

Authors:  D J Coster; K R Wilhelmus; R Michaud; B R Jones
Journal:  Br J Ophthalmol       Date:  1980-10       Impact factor: 4.638

4.  The treatment of herpes simplex virus epithelial keratitis.

Authors:  K R Wilhelmus
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 5.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

Review 6.  Antiviral therapy. Respiratory infections, genital herpes, and herpetic keratitis.

Authors:  K G Nicholson
Journal:  Lancet       Date:  1984-09-15       Impact factor: 79.321

Review 7.  Rational acyclovir therapy in herpetic eye disease.

Authors:  M G Falcon
Journal:  Br J Ophthalmol       Date:  1987-02       Impact factor: 4.638

Review 8.  Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

9.  Aciclovir and trifluorothymidine in herpetic keratitis. Preliminary report of a multicentered trial.

Authors:  C la Lau; J A Oosterhuis; J Versteeg; G van Rij; J G Renardel de Lavalette; A Craandijk; W R Lamers; T Mierlobensteyn
Journal:  Doc Ophthalmol       Date:  1981-03-20       Impact factor: 2.379

10.  Corneal epithelial dysplasia after trifluridine use.

Authors:  P C Maudgal; B Van Damme; L Missotten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.